$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

$hcsg Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000073101218000051 Filed on April 27, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$501.8M	$404.5M
YoY Change	24.06%	5.12%
Cost Of Revenue	$469.3M	$345.6M
YoY Change	35.79%	4.7%
Gross Profit	$32.56M	$58.92M
YoY Change	-44.74%	7.59%
Gross Profit Margin	6.49%	14.57%
Selling, General & Admin	$33.78M	$28.21M
YoY Change	19.73%	11.3%
% of Gross Profit	103.74%	47.88%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.410M	$1.886M
YoY Change	27.78%	-4.02%
% of Gross Profit	7.4%	3.2%
Operating Expenses	$33.78M	$28.21M
YoY Change	19.73%	11.3%
Operating Profit	-$1.219M	$30.71M
YoY Change	-103.97%	4.4%
Interest Expense	-$724.0K	$1.600M
YoY Change	-145.25%	700.0%
% of Operating Profit		5.21%
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.395M	$32.28M
YoY Change	-104.32%	9.04%
Income Tax	-$1.467M	$10.26M
% Of Pretax Income		31.79%
Net Earnings	$72.00K	$22.02M
YoY Change	-99.67%	18.21%
Net Earnings / Revenue	0.01%	5.44%
Basic Earnings Per Share	$0.00	$0.30
Diluted Earnings Per Share	$0.00	$0.30
COMMON SHARES
Basic Shares Outstanding	73.91M shares	73.07M shares
Diluted Shares Outstanding	74.73M shares	73.95M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$84.90M	$116.5M
YoY Change	-27.12%	14.78%
Cash & Equivalents	$10.49M	$48.23M
Short-Term Investments	$74.40M	$68.30M
Other Short-Term Assets	$27.00M	$16.80M
YoY Change	60.71%	7.01%
Inventory	$42.30M	$37.30M
Prepaid Expenses	$27.00M	$16.82M
Receivables	$335.0M	$281.1M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$489.2M	$451.7M
YoY Change	8.29%	15.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.49M	$13.40M
YoY Change	0.67%	0.92%
Goodwill	$51.08M	$44.44M
YoY Change	14.96%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.258M	$48.00K
YoY Change	2520.83%	9.09%
Total Long-Term Assets	$171.7M	$113.4M
YoY Change	51.39%	1.61%
TOTAL ASSETS
Total Short-Term Assets	$489.2M	$451.7M
Total Long-Term Assets	$171.7M	$113.4M
Total Assets	$660.8M	$565.1M
YoY Change	16.93%	12.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$70.62M	$47.95M
YoY Change	47.28%	20.56%
Accrued Expenses	$74.10M	$61.30M
YoY Change	20.88%	-2.39%
Deferred Revenue
YoY Change
Short-Term Debt	$26.00M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$171.6M	$117.7M
YoY Change	45.88%	14.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$94.80M	$91.00M
YoY Change	4.18%	4.0%
Total Long-Term Liabilities	$94.80M	$91.00M
YoY Change	4.18%	4.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$171.6M	$117.7M
Total Long-Term Liabilities	$94.80M	$91.00M
Total Liabilities	$266.5M	$208.6M
YoY Change	27.76%	9.73%
SHAREHOLDERS EQUITY
Retained Earnings	$149.7M	$139.3M
YoY Change	7.47%	24.01%
Common Stock	$254.4M	$226.8M
YoY Change	12.18%	7.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$9.542M	$9.835M
YoY Change	-2.98%	-7.97%
Treasury Stock Shares	1.469M shares	1.541M shares
Shareholders Equity	$394.3M	$356.5M
YoY Change
Total Liabilities & Shareholders Equity	$660.8M	$565.1M
YoY Change	16.93%	12.33%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$72.00K	$22.02M
YoY Change	-99.67%	18.21%
Depreciation, Depletion And Amortization	$2.410M	$1.886M
YoY Change	27.78%	-4.02%
Cash From Operating Activities	$23.93M	$34.65M
YoY Change	-30.93%	257.58%
INVESTING ACTIVITIES
Capital Expenditures	$1.335M	$1.325M
YoY Change	0.75%	-9.18%
Acquisitions
YoY Change
Other Investing Activities	-$2.900M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$4.202M	-$1.356M
YoY Change	209.88%	-63.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$24.00K	$24.00K
YoY Change	0.0%	-14.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$18.80M	-$8.913M
YoY Change	110.89%	-11.64%
NET CHANGE
Cash From Operating Activities	$23.93M	$34.65M
Cash From Investing Activities	-$4.202M	-$1.356M
Cash From Financing Activities	-$18.80M	-$8.913M
Net Change In Cash	$932.0K	$24.38M
YoY Change	-96.18%	-699.09%
FREE CASH FLOW
Cash From Operating Activities	$23.93M	$34.65M
Capital Expenditures	$1.335M	$1.325M
Free Cash Flow	$22.60M	$33.32M
YoY Change	-32.19%	304.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	hcsg	Lineof Credit Facility Increase Decrease Remaining Borrowing Capacity LineofCreditFacilityIncreaseDecreaseRemainingBorrowingCapacity	-65900000	USD
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	73712000	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	hcsg	Period Of Amortization Of Inventories And Supplies PeriodOfAmortizationOfInventoriesAndSupplies	P24M
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000731012
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	HEALTHCARE SERVICES GROUP INC
CY2018Q1	hcsg	Accounts And Notes Receivable Corporate Restructuring Numberof Operators AccountsAndNotesReceivableCorporateRestructuringNumberofOperators	2	operator
CY2018Q1	hcsg	Accounts And Notes Receivable Reclassified From Current To Noncurrent AccountsAndNotesReceivableReclassifiedFromCurrentToNoncurrent	25000000	USD
CY2017Q4	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	390705000	USD
CY2018Q1	hcsg	Accounts Notes Loansand Financing Receivable Gross Current AccountsNotesLoansandFinancingReceivableGrossCurrent	383919000	USD
CY2017Q4	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
CY2018Q1	hcsg	Concentration Risk Numberof Financial Institutions Holding Cashand Cash Equivalentsand Marketable Securities ConcentrationRiskNumberofFinancialInstitutionsHoldingCashandCashEquivalentsandMarketableSecurities	1	financial_institution
CY2018Q1	hcsg	Decrease In Impaired Notes Receivable DecreaseInImpairedNotesReceivable	0	USD
CY2018Q1	hcsg	Decrease In Reserved For Impaired Notes Receivable DecreaseInReservedForImpairedNotesReceivable	0	USD
CY2017Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	-246000	USD
CY2018Q1	hcsg	Increase Decrease In Deferred Compensation Funding IncreaseDecreaseInDeferredCompensationFunding	259000	USD
CY2017Q1	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
CY2018Q1	hcsg	Related Party Transaction Fees Paid Related Party As Percentage Of Overall Related Party Revenues RelatedPartyTransactionFeesPaidRelatedPartyAsPercentageOfOverallRelatedPartyRevenues	0.05
CY2018Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	300000	USD
CY2018Q1	hcsg	Revenue From Contract With Customer Minimum Agreement Period For Account Of Unsatisfied Performance Obligations RevenueFromContractWithCustomerMinimumAgreementPeriodForAccountOfUnsatisfiedPerformanceObligations	P12M
CY2017Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	394196000	USD
CY2018Q1	hcsg	Increase In Impaired Notes Receivable IncreaseInImpairedNotesReceivable	150000	USD
CY2018Q1	hcsg	Increase In Reserved For Impaired Notes Receivable IncreaseInReservedForImpairedNotesReceivable	2752000	USD
CY2018Q1	hcsg	Line Of Credit Facility Number Of Financial Covenants LineOfCreditFacilityNumberOfFinancialCovenants	1	financial_covenant
CY2018Q1	hcsg	Revenue From Contract With Customer Renewable Service Term Period RevenueFromContractWithCustomerRenewableServiceTermPeriod	P1Y
CY2018Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	373828000	USD
CY2017Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	378720000	USD
CY2018Q1	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	335014000	USD
CY2018Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	939000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22495000	USD
CY2018Q1	hcsg	Service Agreements Duration Of Service ServiceAgreementsDurationOfService	P1Y
CY2018Q1	hcsg	Share Based Compensation Arrangement By Share Based Payment Award Maximum Term Of Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumTermOfGrants	P10Y
CY2017Q1	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	39.38
CY2018Q1	hcsg	Share Based Compensation Shares Authorized Under Stock Option Plan Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlanExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	52.06
CY2017Q1	hcsg	Unrealized Gain Loss On Securities Related To Deferred Compensation Fund UnrealizedGainLossOnSecuritiesRelatedToDeferredCompensationFund	1209000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	74463000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	70624000	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	15378000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	22823000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	837000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-301000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	244363000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	253692000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1408000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1580000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1569000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	11985000	USD
CY2018Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	48905000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2018Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	500000	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	200000	shares
CY2017Q4	us-gaap	Assets Assets	676003000	USD
CY2018Q1	us-gaap	Assets Assets	660807000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	527406000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	489153000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1169000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	301000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	197000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	769000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	72249000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	74840000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	22851000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	22914000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	15948000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	16330000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	33506000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	34160000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	916000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	968000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73221000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	74372000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-48000	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-89000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23853000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48230000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9557000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10489000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24377000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	932000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3000000	shares
CY2018Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.19125
CY2017Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.18750
CY2018Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.19250
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74960000	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75169000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73436000	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	73701000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	750000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	752000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22496000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1066000	USD
CY2018Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2017Q1	us-gaap	Cost Of Services CostOfServices	345570000	USD
CY2018Q1	us-gaap	Cost Of Services CostOfServices	469904000	USD
CY2017Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	29429000	USD
CY2018Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	29595000	USD
CY2017Q4	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	28885000	USD
CY2018Q1	us-gaap	Deferred Compensation Plan Assets DeferredCompensationPlanAssets	29443000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	7498000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	7802000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	1300000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	1300000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1886000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2410000	USD
CY2018Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14189000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32139000	USD
CY2018Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	5636000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	12853000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13969000	USD
CY2017Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	2884000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	48040000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18800000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y2M
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6690000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4165000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	3246000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3169000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4165000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4165000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4165000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	30881000	USD
CY2018Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	29766000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	51084000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	51084000	USD
CY2018Q1	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2017Q4	us-gaap	Impaired Financing Receivable Recorded Investment ImpairedFinancingReceivableRecordedInvestment	6854000	USD
CY2018Q1	us-gaap	Impaired Financing Receivable Recorded Investment ImpairedFinancingReceivableRecordedInvestment	7004000	USD
CY2016	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2018Q1	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	32279000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1395000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10262000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1467000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1500000	USD
CY2018Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1100000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	10412000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	16769000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1852000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-13291000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	1059000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	1024000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-506000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-119000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3639000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-5478000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	15299000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	18546000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2859000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3483000	USD
CY2017Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	784000	USD
CY2018Q1	us-gaap	Increase Decrease In Workers Compensation Liabilities IncreaseDecreaseInWorkersCompensationLiabilities	3443000	USD
CY2017Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	343000	USD
CY2018Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	339000	USD
CY2017Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1569000	USD
CY2018Q1	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	476000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	676003000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	660807000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	184168000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	171643000	USD
CY2017Q4	us-gaap	Line Of Credit LineOfCredit	35382000	USD
CY2018Q1	us-gaap	Line Of Credit LineOfCredit	26000000	USD
CY2018Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	300000000	USD
CY2018Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	208100000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	73221000	USD
CY2018Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	74372000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8913000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18797000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1356000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4202000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34646000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23931000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	22017000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	72000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	15476000	USD
CY2018Q1	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	38814000	USD
CY2017Q4	us-gaap	Notes Receivable Net NotesReceivableNet	36600000	USD
CY2018Q1	us-gaap	Notes Receivable Net NotesReceivableNet	60900000	USD
CY2018Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2017Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	446000	USD
CY2018Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-1208000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4561000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3123000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1264000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1258000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	479000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1138000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-500000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	300000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	479000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1138000	USD
CY2017Q4	us-gaap	Other Inventory OtherInventory	42393000	USD
CY2018Q1	us-gaap	Other Inventory OtherInventory	42274000	USD
CY2017Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	13624000	USD
CY2018Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14100000	USD
CY2018Q1	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14149000	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	7858000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5397000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1325000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1335000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	23515000	USD
CY2018Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	27004000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24000	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	0	USD
CY2018Q1	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-9382000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7500000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7723000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2467000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	2400000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	104000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	63000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4687000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4710000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	36004000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	36310000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13509000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13487000	USD
CY2017Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1050000	USD
CY2018Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	37137000	USD
CY2017Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-33000	USD
CY2018Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-70000	USD
CY2017Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
CY2018Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	120000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	163860000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	149743000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	404490000	USD
CY2018Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	501810000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28210000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33777000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	445000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	421000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P5Y
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.019
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.015
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.251
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.214
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.020
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	500000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1231000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.76
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3500000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4200000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	16000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	169000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.52
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.48
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31016000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2374000	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2350000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.22
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.90
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	28.19
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	35.51
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	52.06
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	23043000	USD
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M0D
CY2018Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y5M31D
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	177000	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Dividend Reinvestment Plan StockIssuedDuringPeriodValueDividendReinvestmentPlan	24000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	480000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2820000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	205000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4710000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	399952000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	394344000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1524000	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1469000	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	9858000	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	9542000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	872000	shares
CY2018Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	812000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73946000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	74725000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73074000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	73913000	shares
CY2017Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	22245000	USD
CY2018Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	22917000	USD
CY2017Q4	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	62454000	USD
CY2018Q1	us-gaap	Workers Compensation Liability Noncurrent WorkersCompensationLiabilityNoncurrent	65225000	USD
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The financial instruments that are subject to concentrations of credit risk are cash and cash equivalents, marketable securities, deferred compensation funding and accounts and notes receivable. The Company’s marketable securities are fixed income investments which are highly liquid and can be readily purchased or sold through established markets. At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, substantially all of the Company’s cash and cash equivalents and marketable securities were held in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> large financial institution located in the United States.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s clients are concentrated in the healthcare industry and are primarily providers of long-term care. The revenues of many of the Company’s clients are highly reliant on Medicare, Medicaid and third party payors’ reimbursement funding rates. New legislation or changes in existing regulations could directly impact the governmental reimbursement programs in which the clients participate. As a result, the Company may not know the full effects of such programs until these laws are fully implemented and governmental agencies issue applicable regulations or guidance.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing financial statements in conformity with U.S. GAAP, estimates and assumptions are made that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities, and the reported amounts of revenues and expenses. Actual results could differ from those estimates. Significant estimates are used in determining, but are not limited to, the Company’s allowance for doubtful accounts, accrued insurance claims, valuations, deferred taxes and reviews for potential impairment. The estimates are based upon various factors including current and historical trends, as well as other pertinent industry and regulatory authority information. Management regularly evaluates this information to determine if it is necessary to update the basis for its estimates and to adjust for known changes.</font></div></div>

Files In Submission

Name	View Source	Status
0000731012-18-000051-index-headers.html	Edgar Link	pending
0000731012-18-000051-index.html	Edgar Link	pending
0000731012-18-000051.txt	Edgar Link	pending
0000731012-18-000051-xbrl.zip	Edgar Link	pending
ceosection302certification.htm	Edgar Link	pending
cfosection302certification.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hcsg-20180331.xml	Edgar Link	completed
hcsg-20180331.xsd	Edgar Link	pending
hcsg-20180331_cal.xml	Edgar Link	unprocessable
hcsg-20180331_def.xml	Edgar Link	unprocessable
hcsg-20180331_lab.xml	Edgar Link	unprocessable
hcsg-20180331_pre.xml	Edgar Link	unprocessable
hcsg10qq12018.htm	Edgar Link	pending
healthcareservicesgroupinc.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
section906certificationq12.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg

2018 Q1 Form 10-Q Financial Statement

#000073101218000051 Filed on April 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG HEALTHCARE SERVICES GROUP INC Stock $hcsg

2018 Q1 Form 10-Q Financial Statement

#000073101218000051 Filed on April 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HCSG
HEALTHCARE SERVICES GROUP INC Stock $hcsg